Eldepryl prescribing information |
|
 |
|
Eldepryl notes
Eldepryl available under brand name of Selegiline, Jumex and Deprenyl is used for the treatment of early-stage Parkinson's disease, depression and senile dementia.
Eldepryl is already used successfully to treat canine cognitive dysfunction syndrome (CDS) in dogs.
The standard recommended Eldepryl dosage for Parkinson's disease is 5 mg twice a day. Seek emergency medical attention if you think you have used too much of this medicine.
If a dose is missed, it is advised to consume it as soon as it is remembered. If it is near the time of the next dose, the missed one should be skip and the usual dosing schedule should be resume and strictly not to double the dose to catch up.
Customers can buy eldepryl from the reliable and trustworthy online pharmaceutical sites.
Eldepryl is also available under brand name of jumex and deprenyl.
Chronic treatment of aged rats with deprenyl prevents age-induced protein oxidation in substantia nigra and protects tyrosine hydroxylase enzyme against inactivation.
Eldepryl
Eldepryl helps in breaking down the chemical in our brain called as dopamine. The low level of such chemical indicates the symptoms of Parkinson’s disease. It is recommended not to take alcohol or take foods which are high in tyramine. There are possibilities on increasing sexual urges and unusual urges to gamble while taking this medication. It is also effective as an antidepressant and as a protector against Alzheimer's disease. The recommended dosage is of 5 mg per week. Eldepryl provides selective protection against the age-related degeneration of the dopaminergic nervous
Description:
Eldepryl works by helping to conserve the amount of dopamine available by preventing the dopamine from being destroyed. While controversial, there is some evidence that this drug may slow the progression of Parkinson's disease, particularly early in the course of the disease. This drug is well-tolerated by most people, so many experts recommend using it despite the controversies.
to treat Parkinson's disease. Parkinson's disease is associated with low levels of a chemical called dopamine (doe PA meen) in your brain. The exact way that Eldepryl works is unknown. However, it is believed that Eldepryl prevents the breakdown of dopamine in your brain. Eldepryl is usually added to a treatment regimen after levodopa / carbidopa therapy begins to deteriorate.
Eldepryl is also used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease. It is also used to treat the same muscular conditions when they are caused by drugs such as chlorpromazine (Thorazine), fluphenazine (Prolixin), perphenazine (Trilafon), and others. Eldepryl may also be used for purposes other than those listed in this medication guide.
Drug Mechanism:
Eldepryl provides selective protection against the age-related degeneration of the dopaminergic nervous system. It protects sensitive dopamine-containing neurons from the age-associated increases in glial cells (non-neuron brain cells) and the monoamine oxidase (type B) that they contain. Eldepryl is the first selective inhibitor of MAO-B ever discovered, it is the only one used in clinical practice, and it remains the scientific reference standard for B-type inhibition after more than 40 years.
Eldepryl also competitively inhibits the uptake of dopamine, norepinephrine and epinephrine (collectively referred to as catecholamines) into neurons. This unique ability among the MAO inhibitors prevents the “cheese effect,” a dangerous hypertensive reaction caused by neural uptake of tyramine from tyramine-containing foods like aged cheeses, certain wines, yeast, beans, chicken liver and herring. Eldepryl exhibits no significant cheese effect at therapeutic dosages, and only minimal effects at extremely high dosages.
Eldepryl is a drug that was discovered around 1964-65. It was originally developed as a “psychic energizer,” designed to integrate some amphetamine-like brain effects with antidepressant effects. Also known as L-deprenyl, (-)-deprenyl, and selegiline, Eldepryl has been intensively researched over the past 36 years - many hundreds of research papers on Eldepryl have been published. Eldepryl has been shown to protect nerve cells against a wide (and growing) number of neurotoxins. Eldepryl has also been shown to be a “neuroprotection/ neurorescue agent” when nerve cells are exposed to damaging or stressful conditions.
Dosages:
The dose of Eldepryl will be different for different patients. Your doctor will determine the proper dose of Eldepryl for you. Follow your doctor's orders or the directions on the label.
For the treatment of Parkinson's disease, the usual dose of Eldepryl is 5 mg two times a day, taken with breakfast and lunch. Some patients may need less than this.
Drug Interactions:
Eldepryl can interact with other medications such as Demerol, and many depression medications. Be sure to talk to your doctor about any other medication you are taking before taking Eldepryl. Although Eldepryl is less likely than non-selective monoamine oxidase inhibitors to interact with tyramine in food, like other monoamine oxidase inhibitors it can produce life-threatening reactions when given with pethidine. Zornberg GL, et al. severe adverse interaction between pethidine and Eldepryl.
Pregnancy:
Eldepryl has not been studied in pregnant women. However, this medicine has not been shown to cause birth defects or other problems in animal studies.
Dietary and Alcohol Considerations:
Alcoholic beverages or alcohol-free or reduced-alcohol beer and wine.
Foods that have a high tyramine content (most common in foods that are aged or fermented to increase their flavor), such as cheeses; fava or broad bean pods; yeast or meat extracts; smoked or pickled meat, poultry, or fish; fermented sausage (bologna, pepperoni, salami, summer sausage) or other fermented meat; sauerkraut; or any overripe fruit. If a list of these foods and beverages is not given to you, ask your health care professional to provide one.
Possible Side Effects:
Common side effects are nausea and vomiting. The most frequent side effects also include chest pain (severe); enlarged pupils; fast or slow heartbeat; headache (severe); increased sensitivity of eyes to light; increased sweating (possibly with fever or cold, clammy skin); nausea and vomiting (severe); stiff or sore neck.
Storage:
Keep this medication in the container it came in, tightly closed, and out of reach of children. Eldepryl should be stored at below 30°C (86°F) and away from excess heat and moisture (not in the bathroom). Heat or moisture may cause the medicine to break down. Keep away from light. Talk to your pharmacist about the proper disposal of your medication. Throw away any medication that is outdated or no longer needed. Be sure that any discarded medicine is out of the reach of children.
Packing:
Box of 30 tablets, 5 mg and 10 mg.
2010 May 25;5:149-56.
Leegwater-Kim J, Bortan E.
Function of rasagiline in curing Parkinson's disease
2010 May;42(5):348-50.
Yosunkaya E et all.
Visible improvement in syndrome of segawa during treatment of l-dopa and selegiline
2010 Jul;20(7):459-62.
Watanabe T et all.
Working features of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22)
2010 Mar;16 Suppl Implications:S87-93.
Chen JJ.
Details with respect to Parkinson's disease
2009 Dec 8;73(23):1975-81. Epub 2009 Nov 4.
Schifitto G et all.
Stress level of oxidative and Selegiline in HIV induced cognitive impairment
2009 Sep;10(7):754-80.
Di YM et all.
Details of human cytochrome P450 2A6.
2009 Aug 25;73(8):633-7.
Porta F et all.
Anti - dopamine in 6-pyruvoyl tetrahydropterin synthase deficiency
2009 Aug;5(4):413-9. Epub 2009 Jun 4.
Malaty IA, Fernandez HH.
Responsibility of rasagiline in curing Parkinson's disease
2008 Nov;9(16):2881-91.
Löhle M, Storch A.
In order to cure Parkinson’s disease oral disintegrated selegiline required
2008 Nov;9(16):2759-72.
Elmer LW et all.
Evaluating function of monoamine oxidase type B inhibitors in Parkinson's disease therapy
2008 Oct;76(10):594-9. Epub 2008 Oct 2.
Jost WH, et all.
Clinical trial with respect to rasagiline
2008;23 Suppl 2:S482-8.
Giladi N.
Pharmaceutical help when treated freezing of gait
2007;13 Suppl 3:S446-9.
Antonini A.
Innovative ways adopted in motor parkinsonism
2007 Jun;3(3):467-74.
Lecht S et all.
An innovative mao inhibitor - Rasagiline
2007 Dec;27(12 Pt 2):174S-185S.
Fernandez HH, Chen JJ.
Requirement of Monoamine oxidase-B inhibition while curing Parkinson's disease
2007 Aug 15;31(6):1153-63. Epub 2007 May 10.
Pae CU et all.
Present status and inquisitiveness of Selegiline transdermal system
Eldepryl review article...
|
|
Antiparkinson agents
 Eldepryl prescribing information
Buy here
|
|
My Basket
